IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.62
+3.33%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$27.12
From 52W high−38.57%
Volume1.38M
Market cap$5.70B
P/E (TTM)—
P/S (TTM)804.1x
Div yield—
Key dataOct 19, 2026
Open
$27.12
From 52W high
−38.57%
Volume
1.38M
Market cap
$5.70B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.1x
P/E (TTM)
—
RSI (14)
20.3
MomentumView details →
1D Return
+3.33%
YTD Return
+8.06%
SummaryUpdated Jun 1, 2026
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. The company went public in June 2019 and operates as a subsidiary of Roivant Sciences Ltd. Immunovant focuses on developing innovative monoclonal antibody treatments for autoimmune diseases, with its lead drug candidate batoclimab currently advancing through multiple Phase II clinical trials for various autoimmune conditions.
Similar companies
Latest newsMore news →
Kuehn Law, PLLC said it is investigating whether Immunovant officers and directors breached fiduciary duties to shareholders through potential self-dealing.7d agoSueWallSt notified investors of a pending investigation into potential securities law violations by Immunovant on behalf of IMVT investors who lost money.24d agoImmunovant announced topline results from Period 1 of its proof-of-concept trial of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus, which did not achieve statistical significance on the primary endpoint of CLASI-A percent change from baseline at Week 12 and did not meet the company's internal bar to continue development in CLE.27d ago